Metabolites of the angiotensin II antagonist tasosartan: The importance of a second acidic group

被引:13
作者
Ellingboe, JW
Collini, MD
Quagliato, D
Chen, J
Antane, M
Schmid, J
Hartupee, D
White, V
Park, CH
Tanikella, T
Bagli, JF
机构
[1] Wyeth Ayerst Res, Div Chem Sci, Princeton, NJ 08543 USA
[2] Wyeth Ayerst Res, Div Cardiovasc & Metab Disorders, Princeton, NJ 08543 USA
[3] Wyeth Ayerst Res, Div Struct Biol, Princeton, NJ 08543 USA
关键词
D O I
10.1021/jm970690q
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Described in this paper is the synthesis and pharmacological activity of five metabolites of the angiotensin II antagonist tasosartan (1). Of particular interest is the effect of the additional acidic group of the enol metabolite (8) on activity. As suggested by the structural-activity relationship of other angiotensin II antagonist series, a second acidic group can improve receptor binding activity but decrease in vivo activity after oral dosing. The metabolic introduction of a second acidic group in tasosartan bypasses this problem and contributes to the excellent profile of the compound. A molecular modeling study provides a rationale for the role of the enol group of 8 in AT(1) receptor binding.
引用
收藏
页码:4251 / 4260
页数:10
相关论文
共 16 条
[1]   PYRIDO[2,3-D]PYRIMIDINE ANGIOTENSIN-II ANTAGONISTS [J].
ELLINGBOE, JW ;
ANTANE, M ;
NGUYEN, TT ;
COLLINI, MD ;
ANTANE, S ;
BENDER, R ;
HARTUPEE, D ;
WHITE, V ;
MCCALLUM, J ;
PARK, CH ;
RUSSO, A ;
OSLER, MB ;
WOJDAN, A ;
DINISH, J ;
HO, DM ;
BAGLI, JF .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (04) :542-550
[2]   THE RENIN-ANGIOTENSIN SYSTEM - IMPORTANCE IN PHYSIOLOGY AND PATHOLOGY [J].
FERRARIO, CM .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1990, 15 :S1-S5
[3]   RENIN INHIBITORS [J].
GREENLEE, WJ .
MEDICINAL RESEARCH REVIEWS, 1990, 10 (02) :173-236
[4]  
HULTIN TA, 1997, INT SOC STUDY XENOBI, V11, P226
[5]   BROMOBENZOFURAN-BASED NONPEPTIDE ANTAGONISTS OF ANGIOTENSIN-II - GR138950, A POTENT ANTIHYPERTENSIVE AGENT WITH HIGH ORAL BIOAVAILABILITY [J].
JUDD, DB ;
DOWLE, MD ;
MIDDLEMISS, D ;
SCOPES, DIC ;
ROSS, BC ;
JACK, TI ;
PASS, M ;
TRANQUILLINI, E ;
HOBSON, JE ;
PANCHAL, TA ;
STUART, PG ;
PATON, JMS ;
HUBBARD, T ;
HILDITCH, A ;
DREW, GM ;
ROBERTSON, MJ ;
CLARK, KL ;
TRAVERS, A ;
HUNT, AAE ;
POLLEY, J ;
EDDERSHAW, PJ ;
BAYLISS, MK ;
MANCHEE, GR ;
DONNELLY, MD ;
WALKER, DG ;
RICHARDS, SA .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (19) :3108-3120
[6]   NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONISTS - SYNTHESIS AND BIOLOGICAL-ACTIVITY OF BENZIMIDAZOLECARBOXYLIC ACIDS [J].
KUBO, K ;
KOHARA, Y ;
IMAMIYA, E ;
SUGIURA, Y ;
INADA, Y ;
FURUKAWA, Y ;
NISHIKAWA, K ;
NAKA, T .
JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (15) :2182-2195
[7]   ANGIOTENSIN CONVERTING ENZYME-INHIBITORS AND MODERATE HYPERTENSION [J].
MCAREAVEY, D ;
ROBERTSON, JIS .
DRUGS, 1990, 40 (03) :326-345
[8]  
Mealy N., 1996, Drugs of the Future, V21, P139
[9]   DERIVATION OF A 3D PHARMACOPHORE MODEL FOR THE ANGIOTENSIN-II SITE ONE RECEPTOR [J].
PRENDERGAST, K ;
ADAMS, K ;
GREENLEE, WJ ;
NACHBAR, RB ;
PATCHETT, AA ;
UNDERWOOD, DJ .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1994, 8 (05) :491-512
[10]  
SAKAMOTO T, 1982, CHEM PHARM BULL, V30, P2410